Cargando…

circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622/CMTM6 axis to promote triple-negative breast cancer and immune escape

BACKGROUND: This study reported the function and mechanism of circ-0000512 in the progression of triple-negative breast cancer (TNBC). METHODS: circ-0000512 expression in TNBC tissues and paired adjacent normal tissues and cells was examined by qRT-PCR. Moreover, circ-0000512 expression in TNBC cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Li-Feng, Chen, Fang-Fang, Fan, Yang-Fan, Zhang, Kun, Chen, Hui-Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314703/ https://www.ncbi.nlm.nih.gov/pubmed/37349124 http://dx.doi.org/10.1136/jitc-2022-005461

Ejemplares similares

Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation
por: Zhu, Lin, et al.
Publicado: (2022)

LINC01140 promotes the progression and tumor immune escape in lung cancer by sponging multiple microRNAs
por: Xia, Rongmu, et al.
Publicado: (2021)

2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1
por: Chen, Zhanfei, et al.
Publicado: (2020)

Circ_0005918 Sponges miR-622 to Aggravate Intervertebral Disc Degeneration
por: Cui, Yan, et al.
Publicado: (2022)

FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer
por: Liu, Jiaxin, et al.
Publicado: (2022)

CUL3/SPOP complex prevents immune escape and enhances chemotherapy sensitivity of ovarian cancer cells through degradation of PD-L1 protein
por: Dong, Min, et al.
Publicado: (2022)

Mesoporous silica nanoparticles inflame tumors to overcome anti-PD-1 resistance through TLR4-NFκB axis
por: Sun, Mayu, et al.
Publicado: (2021)

Targeting ANXA1 abrogates Treg-mediated immune suppression in triple-negative breast cancer
por: Bai, Fang, et al.
Publicado: (2020)

Epstein–Barr Virus–Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L1
por: Ge, Junshang, et al.
Publicado: (2021)

ZEB1 transcription factor promotes immune escape in melanoma
por: Plaschka, Maud, et al.
Publicado: (2022)

THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy
por: Li, Chushu, et al.
Publicado: (2021)

Circular RNA hsa_circ_0067842 facilitates tumor metastasis and immune escape in breast cancer through HuR/CMTM6/PD-L1 axis
por: Li, Juan, et al.
Publicado: (2023)

Knockdown of circ_0000512 Inhibits Cell Proliferation and Promotes Apoptosis in Colorectal Cancer by Regulating miR-296-5p/RUNX1 Axis
por: Wang, Lihong, et al.
Publicado: (2020)

AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells
por: Zhang, Ganggang, et al.
Publicado: (2023)

Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers
por: Hu, Chunhong, et al.
Publicado: (2021)

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
por: Mezzadra, Riccardo, et al.
Publicado: (2017)

IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma
por: Zhang, Wenjie, et al.
Publicado: (2020)

Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
por: Lee, Maxwell Y, et al.
Publicado: (2021)

GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway
por: Rong, Dawei, et al.
Publicado: (2023)

Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy
por: Shen, Wenhui, et al.
Publicado: (2023)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
por: Guo, Weinan, et al.
Publicado: (2020)

Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer
por: Quan, Yibo, et al.
Publicado: (2023)

Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth
por: Heeren, Anne Marijne, et al.
Publicado: (2021)

Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer
por: Cao, Xu, et al.
Publicado: (2021)

Follicular helper-T cells restore CD8(+)-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
por: Niogret, Julie, et al.
Publicado: (2021)

Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression
por: Lv, Tingting, et al.
Publicado: (2022)

Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
por: Liu, Chao, et al.
Publicado: (2021)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
por: Ng, Harry Ho Man, et al.
Publicado: (2020)

Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors
por: Hao, Xingxing, et al.
Publicado: (2021)

Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer
por: Shi, Shuai, et al.
Publicado: (2022)

Tryptophan potentiates CD8(+) T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation
por: Qin, Rui, et al.
Publicado: (2021)

Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy
por: Kortekaas, Kim E, et al.
Publicado: (2021)

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL
por: Zhang, Tingting, et al.
Publicado: (2022)

Analysis of CMTM6 and CMTM4 expression as potential regulators of the PD-L1 protein and its association with prognosis in glioma cancer
por: Xue, Hui, et al.
Publicado: (2022)

PD-1 does not mark tumor-infiltrating CD8+ T cell dysfunction in human gastric cancer
por: Shen, Yang, et al.
Publicado: (2020)

Inhibition of tumor intrinsic BANF1 activates antitumor immune responses via cGAS-STING and enhances the efficacy of PD-1 blockade
por: Wang, Minglei, et al.
Publicado: (2023)

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
por: Park, Ji-Eun, et al.
Publicado: (2020)

DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma
por: Fitzgerald, Allison A, et al.
Publicado: (2021)

CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment
por: Zhang, Tong, et al.
Publicado: (2022)

Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
por: Liu, Huicheng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mm81fra6om9gmk3o8gja8351g4